Literature DB >> 25801898

Combined intramyocardial delivery of human pericytes and cardiac stem cells additively improves the healing of mouse infarcted hearts through stimulation of vascular and muscular repair.

Elisa Avolio1, Marco Meloni1, Helen L Spencer1, Federica Riu1, Rajesh Katare1, Giuseppe Mangialardi1, Atsuhiko Oikawa1, Iker Rodriguez-Arabaolaza1, Zexu Dang1, Kathryn Mitchell1, Carlotta Reni1, Valeria V Alvino1, Jonathan Rowlinson1, Ugolini Livi1, Daniela Cesselli1, Gianni Angelini1, Costanza Emanueli1, Antonio P Beltrami1, Paolo Madeddu2.   

Abstract

RATIONALE: Optimization of cell therapy for cardiac repair may require the association of different cell populations with complementary activities.
OBJECTIVE: Compare the reparative potential of saphenous vein-derived pericytes (SVPs) with that of cardiac stem cells (CSCs) in a model of myocardial infarction, and investigate whether combined cell transplantation provides further improvements. METHODS AND
RESULTS: SVPs and CSCs were isolated from vein leftovers of coronary artery bypass graft surgery and discarded atrial specimens of transplanted hearts, respectively. Single or dual cell therapy (300 000 cells of each type per heart) was tested in infarcted SCID (severe combined immunodeficiency)-Beige mice. SVPs and CSCs alone improved cardiac contractility as assessed by echocardiography at 14 days post myocardial infarction. The effect was maintained, although attenuated at 42 days. At histological level, SVPs and CSCs similarly inhibited infarct size and interstitial fibrosis, SVPs were superior in inducing angiogenesis and CSCs in promoting cardiomyocyte proliferation and recruitment of endogenous stem cells. The combination of cells additively reduced the infarct size and promoted vascular proliferation and arteriogenesis, but did not surpass single therapies with regard to contractility indexes. SVPs and CSCs secrete similar amounts of hepatocyte growth factor, vascular endothelial growth factor, fibroblast growth factor, stem cell factor, and stromal cell-derived factor-1, whereas SVPs release higher quantities of angiopoietins and microRNA-132. Coculture of the 2 cell populations results in competitive as well as enhancing paracrine activities. In particular, the release of stromal cell-derived factor-1 was synergistically augmented along with downregulation of stromal cell-derived factor-1-degrading enzyme dipeptidyl peptidase 4.
CONCLUSIONS: Combinatory therapy with SVPs and CSCs may complementarily help the repair of infarcted hearts.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  acute inferior myocardial infarction; cardiac remodeling, ventricular; cell transplantation; cell- and tissue-based therapy; pericytes; stem cells

Mesh:

Substances:

Year:  2015        PMID: 25801898     DOI: 10.1161/CIRCRESAHA.115.306146

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  60 in total

Review 1.  Potential clinical benefits of cell therapy in coronary heart disease: an update.

Authors:  Vincenzo Grimaldi; Alberto Zullo; Francesco Donatelli; Francesco Paolo Mancini; Francesco Cacciatore; Claudio Napoli
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Early Intravenous Delivery of Human Brain Stromal Cells Modulates Systemic Inflammation and Leads to Vasoprotection in Traumatic Spinal Cord Injury.

Authors:  Anna Badner; Reaz Vawda; Alex Laliberte; James Hong; Mirriam Mikhail; Alejandro Jose; Rachel Dragas; Michael Fehlings
Journal:  Stem Cells Transl Med       Date:  2016-05-31       Impact factor: 6.940

Review 3.  Vascular stem cells-potential for clinical application.

Authors:  Sadie C Slater; Michele Carrabba; Paolo Madeddu
Journal:  Br Med Bull       Date:  2016-06       Impact factor: 4.291

4.  Stimulatory Effects of Mesenchymal Stem Cells on cKit+ Cardiac Stem Cells Are Mediated by SDF1/CXCR4 and SCF/cKit Signaling Pathways.

Authors:  Konstantinos E Hatzistergos; Dieter Saur; Barbara Seidler; Wayne Balkan; Matthew Breton; Krystalenia Valasaki; Lauro M Takeuchi; Ana Marie Landin; Aisha Khan; Joshua M Hare
Journal:  Circ Res       Date:  2016-08-01       Impact factor: 17.367

5.  After the storm: an objective appraisal of the efficacy of c-kit+ cardiac progenitor cells in preclinical models of heart disease.

Authors:  Roberto Bolli; Xian-Liang Tang; Yiru Guo; Qianghong Li
Journal:  Can J Physiol Pharmacol       Date:  2020-09-16       Impact factor: 2.273

6.  Angiokine Wisp-1 is increased in myocardial infarction and regulates cardiac endothelial signaling.

Authors:  Lillianne H Wright; Daniel J Herr; Symone S Brown; Harinath Kasiganesan; Donald R Menick
Journal:  JCI Insight       Date:  2018-02-22

Review 7.  Stem cell-derived vasculature: A potent and multidimensional technology for basic research, disease modeling, and tissue engineering.

Authors:  Justin Lowenthal; Sharon Gerecht
Journal:  Biochem Biophys Res Commun       Date:  2015-09-30       Impact factor: 3.575

8.  Cardiac Nestin+ Mesenchymal Stromal Cells Enhance Healing of Ischemic Heart through Periostin-Mediated M2 Macrophage Polarization.

Authors:  Yan Liao; Guilan Li; Xiaoran Zhang; Weijun Huang; Dongmei Xie; Gang Dai; Shuanghua Zhu; Dihan Lu; Zhongyuan Zhang; Junyi Lin; Bingyuan Wu; Wanwen Lin; Yang Chen; Zhihong Chen; Chaoquan Peng; Maosheng Wang; Xinxin Chen; Mei Hua Jiang; Andy Peng Xiang
Journal:  Mol Ther       Date:  2020-01-15       Impact factor: 11.454

9.  De-novo collateral formation following acute myocardial infarction: Dependence on CCR2⁺ bone marrow cells.

Authors:  Hua Zhang; James E Faber
Journal:  J Mol Cell Cardiol       Date:  2015-08-04       Impact factor: 5.000

10.  Epigenetically modified cardiac mesenchymal stromal cells limit myocardial fibrosis and promote functional recovery in a model of chronic ischemic cardiomyopathy.

Authors:  Joseph B Moore; Xian-Liang Tang; John Zhao; Annalara G Fischer; Wen-Jian Wu; Shizuka Uchida; Anna M Gumpert; Heather Stowers; Marcin Wysoczynski; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2018-11-16       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.